Safety of Omalizumab During Pregnancy and Breast-Feeding With Assessment of Placental Transfer: A Case Report

Asthma exacerbation in pregnant women is associated with obstetrical complications such as fetal growth restriction, preterm delivery and preeclampsia. Omalizumab is a recombinant humanized monoclonal antibody approved for the treatment of severe persistent allergic asthma. Data on its safety during pregnancy, based on case series and registries, are limited. In this case report, we provide an assessment of omalizumab placental transfer and discussed its safety.